Search

Your search keyword '"Earl, HM"' showing total 13 results
Start Over Author "Earl, HM" Journal cancer research
13 results on '"Earl, HM"'

1. Abstract OT3-01-02: PARTNERING / PARTNER : Phase II sub-study to establish if the addition of combinations of new agents (olaparib, cell cycle and immune checkpoint inhibitors) can improve the rate of pathological complete response (pCR) and minimal residual disease (MRD) in triple negative breast cancer (TNBC) and / or germline BRCA mutated (gBRCAm) patients with evidence of residual disease after PARTNER therapy

Author

Abraham, JE, primary, Vallier, A-L, additional, Qian, W, additional, Machin, A, additional, Grybowicz, L, additional, Thomas, S, additional, Weiss, M, additional, Harvey, C, additional, McAdam, K, additional, Hughes-Davies, L, additional, Roberts, A, additional, Provenzano, E, additional, Pinilla, K, additional, Roylance, R, additional, Copson, E, additional, Armstrong, A, additional, McMurtry, E, additional, Tischkowitz, M, additional, and Earl, HM, additional

Published
2019
Full Text
View/download PDF

2. Abstract OT1-05-02: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer

Author

Stein, RC, primary, Hughes-Davies, L, additional, Makris, A, additional, Macpherson, IR, additional, Conefrey, C, additional, Rooshenas, L, additional, Pinder, SE, additional, Thomas, J, additional, Hall, PS, additional, Cameron, DA, additional, Earl, HM, additional, Naume, B, additional, Poole, CJ, additional, Rea, DW, additional, MacIntosh, SA, additional, Harmer, V, additional, Morgan, A, additional, Hulme, C, additional, McCabe, C, additional, Stallard, N, additional, Higgins, H, additional, Donovan, JL, additional, Bartlett, JM, additional, Marshall, A, additional, and Dunn, JA, additional

Published
2019
Full Text
View/download PDF

3. Abstract OT2-01-15: PARTNER - Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients

Author

Abraham, JE, primary, Vallier, A-L, additional, Qian, W, additional, Grybowicz, L, additional, Thomas, S, additional, Mahmud, S, additional, Harvey, C, additional, McAdam, K, additional, Hughes-Davies, L, additional, Roylance, R, additional, Copson, E, additional, Brown, J, additional, Provenzano, E, additional, Tischkowitz, M, additional, and Earl, HM, additional

Published
2017
Full Text
View/download PDF

4. Abstract OT3-02-02: ROSCO: A randomised phase III, stratified CEP17/TOP2A biomarker trial of neo-adjuvant 5-flourouracil, epirubicin and cyclophosphamide vs docetaxel and cyclophosphamide chemotherapy

Author

Rea, DW, primary, Haywood, L, additional, Francis, AM, additional, Bowden, SJ, additional, Brookes, CM, additional, MacKenzie, M, additional, Cameron, D, additional, Stein, R, additional, Earl, HM, additional, Thomas, J, additional, Abraham, J, additional, Stanley, A, additional, Starczinski, J, additional, McGoldrick, T, additional, Treharne-Jones, P, additional, Billingham, L, additional, and Bartlett, JM, additional

Published
2016
Full Text
View/download PDF

5. Abstract OT3-02-12: OPTIMA (optimal personalised treatment of early breast cancer usIng multi-parameter analysis), a prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions

Author

Stein, RC, primary, Marshall, A, additional, Hall, PS, additional, Bartlett, JMS, additional, Rooshenas, L, additional, Campbell, A, additional, Cameron, DA, additional, Rea, D, additional, Macpherson, I, additional, Earl, HM, additional, Poole, CJ, additional, Francis, A, additional, Morgan, A, additional, Harmer, V, additional, Pinder, SE, additional, Stallard, N, additional, Donovan, J, additional, Hulme, C, additional, McCabe, C, additional, Hughes-Davies, L, additional, Makris, A, additional, and Dunn, JA, additional

Published
2016
Full Text
View/download PDF

13. Immunohistochemical study of beta- and kappa-casein in the human breast and breast carcinomas, using monoclonal antibodies.

Author

Earl HM, McIlhinney RA, Wilson P, Gusterson BA, and Coombes RC

Subjects
Antibodies, Monoclonal, Breast pathology, Enzyme-Linked Immunosorbent Assay, Female, Fibrocystic Breast Disease pathology, Humans, Immunohistochemistry, Lactation physiology, Reference Values, Breast cytology, Breast Neoplasms pathology, Caseins analysis, Pregnancy physiology
Abstract

The immunohistochemical analysis of human beta- and kappa-caseins in the human breast, benign breast disease, and breast carcinomas is reported. The monoclonal antibodies LICR-LON-32.2 and LICR-LON-14.1 which react with human beta- and kappa-casein, respectively (Earl, H. M., and McIlhinney, R. A. J. Mol. Immunol., 22: 981-991, 1985) were used for these studies. Human beta- and kappa-caseins were detected in lactating human breast tissue, lactational foci in the resting breast, and heterogeneously in the 16th-week pregnant breast, but not in normal breast tissue. In benign breast disease occasional epithelial cells were demonstrated to synthesize beta- and kappa-caseins, but this finding did not appear to correlate with the hormonal status or previous obstetric histories of the patients. However, similar studies in 45 breast carcinomas with a wide range of estrogen receptor content, demonstrated no detectable beta- or kappa-casein. These results demonstrate that the caseins, which are biochemical markers of mammary gland differentiated function, and have been previously put forward as markers of breast cancer, were not synthesized in the 45 human breast carcinomas studied here, even in tumors with high levels of estrogen receptor protein.

Published
1989

Catalog

Books, media, physical & digital resources
See catalog results